Actively Recruiting
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
Led by Eli Lilly and Company · Updated on 2025-10-20
120
Participants Needed
2
Research Sites
16 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.
CONDITIONS
Official Title
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy status without any clinically significant active or chronic disease
- Body mass index (BMI) between 18.0 and 30.0 kilograms per square meter (kg/m²), inclusive
- Assigned male or female at birth and not of childbearing potential (INOCBP)
You will not qualify if you...
- Females who are lactating or of childbearing potential
- History of any significant drug sensitivity, drug allergy, or food allergy
- Use of medication within 14 days or 5 half-lives prior to admission, except occasional acetaminophen at doses \u22642 g/day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
ICON Early Phase Services
San Antonio, Texas, United States, 78209
Actively Recruiting
2
ICON
Salt Lake City, Utah, United States, 84124
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here